Patient Specific Brain Organoids for In Vitro Modeling of Parkinson's Disease

Explore the cutting-edge application of patient-specific brain organoids in Parkinson's disease research through this 23-minute webinar presented by Dr. Gemma Gomez Giro from OrganoTherapeutics. Discover how three-dimensional midbrain organoids serve as revolutionary in vitro models that recapitulate key features of the human brain, including dopaminergic, glutamatergic, GABAergic, and serotonergic neurons alongside supporting cell types like astrocytes, oligodendrocytes, and microglia. Learn about the sophisticated methodologies used to model disease-relevant phenotypes such as dopaminergic neuron loss, alpha-Synuclein aggregate formation, and neuroinflammation in laboratory settings. Understand how these complex organoid systems enable researchers to screen for therapeutic efficacy across diverse treatment modalities, from small molecule drugs to anti-sense oligonucleotides and peptides. Gain insights into the phenotypic approaches that allow detection of disease-associated conditions and their potential amelioration through drug treatments. Examine the ongoing developments in computational tools and deep phenotyping assays that enhance the detection of cellular defects and therapeutic rescue mechanisms. The presentation covers the transition from traditional disease modeling to patient-specific approaches that better represent individual variations in Parkinson's disease pathology. Discover the interdisciplinary collaboration aspects of modern neurodegenerative disease research, including the integration of on-chip technologies and systems biomedicine approaches. The webinar also addresses the broader implications of organoid technology for drug discovery and development in neurodegeneration research, providing valuable perspectives for researchers, clinicians, and biotechnology professionals working in neuroscience and therapeutic development.